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Abstract
Background: Human papillomavirus (HPV) 16 and 18 are associated with cervical carcinogenesis
through an interaction between HPV oncogenic proteins and cell cycle regulatory genes. However,
the exact pathogenetic mechanisms are not determined yet.
Methods: We investigated 43 invasive squamous cell carcinoma (ISCC), 38 CIN III, 11 CINII and
18 CINI for cyclin D1, cyclin E, CDK4, p53, mdm-2, p21waf, p27, p16INK4A, Rb and Ki-67 aberrations
using immunohistochemistry and molecular techniques. Twenty samples of normal cervical tissues
(NCT) were taken as a control.
Results: There was a significant increase in the expression of Ki-67, cyclin E, CDK4, p16INK4A, Rb (p=
0.003, 0.001, 0.001, 0.01) and a significant decrease in p27KIP1 from NCT to ISCC (p = 0.003).
Increased cyclin D1, p21waf, p53, mdm-2 expression, homozygous deletion (HZD) and promoter
methylation (PM) of the Rb were detected in CINIII and ISCC only. On univariate analysis; tumor
size, differentiation, lymph node status, FIGO stage, Ki- 67, cyclin D1, p53 and p27KIP1 are significantly
associated with reduced overall survival (OS) while on multivariate analysis; only FIGO stage, Ki-67,
cyclin D1, p53 and p27KIP1 were significant.
Conclusion: 1) Aberrations involving p27KIP1, cyclin E, CDK4, p16INK4A are considered early events
in HPV 16 and 18-associated cervical carcinoma, whereas cyclin D1 and p53 pathway abnormalities
are considered late events. 2) Immunohistochemical tests for p16INK4Aand cyclin E, could help in
early diagnosis of cervical carcinoma. 3) Only FIGO stage p53, cyclin D1, p27KIP1 and Ki-67 are
independent prognostic factors that might help in predicting outcome of cervical cancer patients.
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Background
Carcinoma of the uterine cervix emerges from a defined
series of prenoplastic lesions with increasing cellular dys-
plasia referred to as cervical intraepithelial neoplasia
(CIN) grade I, II and III [1]. A large body of knowledge
supports the view that high risk HPV types (HR-HPV) are
strongly associated with invasive squamous cell carci-
noma (ISCC) and its precursors as they have the ability to
transform normal cervical cells into neoplastic ones [2].
HPV 16 and 18 are the most commonly detected HR-HPV
types in these lesions, and therefore their detection was
proposed as a useful surrogate marker to diagnose cervical
dysplasia and carcinoma in situ (CIS) [2,3].
Progress in cervical cancer research provided evidence that
integration of HR-HPV DNA into the host cell genome
results in elevated expression levels of the E6 and E7 pro-
teins with subsequent interaction between these onco-
genic proteins and the cell cycle machinery [2,4].
Expression of E6  and  E7  proteins of HR-HPV types
induces immortalization of cells through their inhibitory
effects on the tumor suppressor proteins pRb  and p53;
respectively, altering the cell cycle control and leading to
chromosomal instability [2]. Undermining of pRb
growth-inhibitory role with release of E2F transcription
factors render the cells independent of mitogenic stimuli
[5], whereas inactivation of the p53 precludes its role as
one of the major factors controlling cell proliferation
since it arrests the cell cycle in response to DNA damage
or direct the damaged cell to an apoptotic pathway. This
function is abolished via p53 degradation by the E6 pro-
tein of oncogenic HPV types or via cytoplasmic sequestra-
tion by complexing to mdm-2 protein [6].
However the E6-p53 and E7-Rb model is not sufficient to
inevitably produce cervical carcinoma although it has
resulted in the identity of the viral gene's actions on
numerous cellular proteins and processes normally
involved in cellular growth and proliferation. This is evi-
denced by the spontaneous clearance of HPV infection
and the long delay between the onset of persistent infec-
tion and the emergence of malignancy. Recent studies
show an association between HR-HPV types and cell cycle
regulators [2,7]. The cell cycle is governed by a family of
cyclins, cyclin dependent kinases (CDKs) and their inhibitors
(CDKIs) through activating and inactivating phosphoryla-
tion events. Attention has been focused on altered expres-
sion of G1 cyclins and Cdks because the major regulatory
events leading to cell proliferation and differentiation
occur within the G1 phase of the cell cycle. The D-type cyc-
lins reach maximum levels of expression and form func-
tional kinase complexes with CDK4 or CDK6; during the
mid-G1 phase, whereas cyclin-E is expressed and associated
with Cdk2 in an active complex near the G1-S boundary
[5,8]. Active CDK/cyclin  complex can be regulated by
binding to CDKI  (p16INK4A, p21waf1  and  p27KIP1) and
inhibit cell cycle progression from G1 to S phase [7].
Deregulation of p16INK4A, p21waf1 and p27KIP1 has recently
been reported in various human tumors. In HPV-associ-
ated cervical carcinoma, the expression and function of
these proteins is supposed to be impaired by the action of
viral oncopoteins E6 and E7 [9]. However, it is unclear
how and when factors that are innate to the HPV-infected
cells including genetic aberrations launch the host cell
into an irreversible progression to cancer [7].
Therefore, we attempted to assess the contribution of cyc-
lin D1, cyclin E, CDK4, p53, mdm-2, p21waf, Rb, p27KIP1,
p16INK4A  and  Ki-67  expression to the development of
HPV16/18-associated cervical carcinoma and to deter-
mine at what stage of carcinogenesis these aberrations
start to manifest. The prognostic value of these aberrations
was also investigated in relation to the standard clinico-
pathological prognostic factors and overall survival.
Methods
Clinical samples
The study included 110 fresh-frozen tissue samples that
were selected from a total of 200 based on the positivity
for HPV16 and/or18 and on the availability of clinical and
follow-up data. The studied cases included 43 invasive
squamous cell carcinoma (ISCC), 38 cervical intra-epithe-
lial neoplasia (CIN) III, 11 CINII and 18 CINI cases were
collected from patients who were diagnosed and treated at
the hospitals of Kasr El-Aini School of Medicine and the
National Cancer Institute (NCI), Cairo University during
March 1999- July 2003 after a recent evidence of abnor-
mal cervical cytology and/or conization biopsy (obtained
by large loop excision of the transformation zone). Cases
of ISCC were examined by two independent pathologists,
classified and graded according to the World Health
Organization (WHO) criteria and staged according to cri-
teria of the International Federation of Gynecolology and
Obstetrics (FIGO) [10]. The clinicopathological features
of the studied cases are illustrated in table 1. Twenty nor-
mal cervical tissues (NCT) obtained from patients under-
going hysterectomy for medical conditions not related to
the cervix were included in the study as a control. All con-
trol samples showed normal cervical cytology and histol-
ogy and all were negative for HPV by PCR. In ISCC and
CIN samples, only cases with ≥ 75% tumor cells were
included in the study. A written consent was obtained
from all patients prior to enrollment in the study, and the
ethical committee of the NCI approved the protocol
which was in accordance with the ethical guidelines of the
1975 Declaration of Helsinki.BMC Clinical Pathology 2007, 7:4 http://www.biomedcentral.com/1472-6890/7/4
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Cell lines
The HPV16 (SiHa), HPV18 (HeLa) positive cervical carci-
noma and the mdm2 positive (SA-1) cell lines (from Insti-
tute of Human Genetics, Academic Medical Centre,
Amsterdam, The Netherlands) were maintained in Dul-
becco's Modified Eagle Medium (DMEM; Sigma, USA)
supplemented with 10% fetal bovine serum (Sigma, USA)
and used as controls.
DNA extraction
High molecular weight DNA was extracted from fresh
tumor and normal samples as well as cell lines, according
to standard protocols [11].
HPV detection and typing
The purified DNA was subjected to PCR amplification
using general-purpose HPV primers (GP5+ and GP6+)
which amplify conserved sequences in the HPV-L1 region
(150 bp) as previously described [12]. PCR products were
separated by electrophoresis on 1.5% agarose gel, trans-
ferred onto a nylon membrane (Hybond N +, Amersham)
and analyzed using digoxigenin-labelled type-specific
probes by chemiluminescent detection (ELOCA). The
HPV probe consisted of a cocktail of 14 high-risk mucosal
types [16, 18, 31, 33, 35, 45, 51, 52, 56, 58, 59, 62, 66,
and 68] and two low-risk types [6 and 11].
Immunohistochemistry
Tumors and normal tissue samples were put in 10% neu-
tral buffered formalin and processed routinely for prepa-
ration of hematoxylin and eosin-stained slides and for
immunohistochemical studies. Five micron thick sections
were cut onto positive-charged slides and used for immu-
nohistochemical detection of cyclin D1, cyclin E, CDK4,
p53, mdm-2, p21waf,p27KIP1, p16INK4A, Rb, and Ki-67. The
standard streptavidin-biotin-peroxidase detection tech-
nique was performed using the antibodies illustrated in
table 2. Briefly, after deparaffinization in xylene and rehy-
dration through graded alcohols, sections were micro-
waved in 0.01 M citrate buffer (pH 6.0) for 15 min.
Endogenous peroxidase activity was blocked by immer-
sion in 0.03% H2O2 in methyl alcohol for 30 min and
Table 1: Clinicopathologic features of invasive squamous cell carcinoma cases in relation to different studied markers.
Clinical 
features
No. = 43 Cyclin D1
n = 18
Cyclin E
n = 38
Cdk-4
n = 40
P27 KIp1
n = 37
P53
n = 19
mdm2
n = 22
P21 waf
n = 29
Rb
n = 30
P16
n = 40
Ki-67
n = 36
Tumor size
<4 cm 1 5 2 1 01 29 2 4 7 1 3 1 31 0
≤4 cm 28 16 28 28 28 17 18 22 27 17 26
(p = 0.003) (p = 0.003) p = 0.047 p = 0.003 p = 0.003 (p = 0.001) (p = 0.008)
Tumor type
LK-SCC 13 7 9 13 7 1 3 10 12 2 8
LNK-SCC 26 10 25 24 26 15 16 17 24 24 24
SmCC 4 1 43 4 3 3 23 44
p = 0.047 p = 0.01 p = 0.01
Stromal 
invasion
<1/2 1 5 6 1 31 5 1 2 7 7 9 9 1 41 2
≤1/2 28 12 25 25 25 12 15 20 21 26 24
p = 0.024 p = 0.037
Lymph nodes
Positive 13 5 9 11 7 2 4 10 7 11 7
Negative 30 13 29 29 30 17 18 19 23 29 29
p = 0.001 p = 0.001
Lympho- 
vascular
Positive 7 5 55 4 2 2 54 56
Negative 36 13 33 35 33 17 20 24 26 35 30
p = 0.035 p = 0.003 p = 0.001
Vaginal 
involvement
Positive 12 6 10 10 7 5 3 8 9 10 11
Negative 31 12 28 30 30 14 19 21 21 30 25
(p = 0.037)
FIGO Stage
I&II 1 7 3 1 51 6 1 2 2 9 1 21 3 1 71 0
III&IV 26 15 23 24 25 17 13 17 17 23 26
(p = 0.008) p = 0.002 p = 0.003 p = 0.019
* LNK-SCC: Large non-keratinized squamous cell carcinoma LNK-SCC: Large keratinized squamous cell carcinoma SmCC: Small cell carcinomaBMC Clinical Pathology 2007, 7:4 http://www.biomedcentral.com/1472-6890/7/4
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10% normal rabbit (for mouse primary antibodies) or
goat serum (for rabbit primary antibodies) was applied to
avoid non-specific reaction. Sections were then incubated
with the primary antibodies or with non-immunized
mouse or rabbit serum for the negative control at 4°C.
After washing with PBS, biotinylated anti-muse or rabbit
IgG was applied for 30 min at room temperature. The per-
oxidase-conjugated-streptavidin solution was applied for
30 min and visualized using 0.05% 3'-3' diaminobenziine
(DAB). Counterstaining was performed with Meyer's
hematoxylin [13].
Only a distinct brown nuclear staining was scored posi-
tive. In NCT, cyclin D1; cyclin E and CDK were focaly
expressed in the parabasal cells only, there was no immu-
nostaining for p53 and mdm-2, p21waf was focally detected,
p27KIP1 was normally detected in > 50% of the cells and Rb
was detected in all NCT samples. This was the normal
expression pattern for the studied protein [8]. An aberrant
expression of cyclin D1, cyclin E, CDK4,  p21waf  and
p16INK4A was defined as staining in excess of normal tis-
sues (> 20% for cyclin D1; cyclin E, CDK4 and > 10% for
p21wafand p16INK4A) (Figure 1). p53 and mdm-2 overexpres-
sion was considered with > 10% positive cells. Loss of
p27KIP1 was defined as staining in < 50% of the cells and
altered expression of Rb was defined as absence of nuclear
staining in all sections examined [8]. Four semiquantita-
tive classes were used to describe the percentage of posi-
tively-stained tumor cells: negative (no cells stained); +:
minimaly positive (1–10% positive cells); ++: moderately
positive (10–50% positive cells); and +++: markedly pos-
itive (> 50% positive cells). The positivity of each stain
including Ki-67 was also described as a positivity index
(PI) which indicated the number of positive cells in 1000
arbitrarily selected, manually counted cells at 200× mag-
nification [4,6,13].
a) Positive immunostaining for p27KIP1 in the nuclei of normal  cervical tissue, b) positive immunostaining for p27KIP1 in CINI,  c) lack of p27KIP1 immunostaining in a case of invasive squa- mous cell carcinoma, d) positive immunostaining for p16INK4A  in a case of CINII, e) positive immunostaining for p16INK4A in a  case of III, f) negative nuclear imminostaining for cyclinD1 in  normal cervical tissue except in the parabasal cells, g) a  strongly positive immunostaining for cyclinD1 in a case of  invasive squamous cell carcinoma, h) positive nuclear immu- nostaining for Rb in parabasal and intermediate squamous  cells in hyperplastic squamous epithelium, and i) focal and  weak nuclear staining for Rb in a case of invasive squamous  cell carcinoma Figure 1
a) Positive immunostaining for p27KIP1 in the nuclei of normal 
cervical tissue, b) positive immunostaining for p27KIP1 in CINI, 
c) lack of p27KIP1 immunostaining in a case of invasive squa-
mous cell carcinoma, d) positive immunostaining for p16INK4A 
in a case of CINII, e) positive immunostaining for p16INK4A in a 
case of III, f) negative nuclear imminostaining for cyclinD1 in 
normal cervical tissue except in the parabasal cells, g) a 
strongly positive immunostaining for cyclinD1 in a case of 
invasive squamous cell carcinoma, h) positive nuclear immu-
nostaining for Rb in parabasal and intermediate squamous 
cells in hyperplastic squamous epithelium, and i) focal and 
weak nuclear staining for Rb in a case of invasive squamous 
cell carcinoma.
Table 2: Summary of specific antisera and immunohistochemistry conditions
Protein Antibody Dilution & incubation Antigen pretreatment Positive control Stain
Cyclin D1 P2D11F11 Novocastra 1:50 Microwave Colon cancer Nuclear
Cyclin E 13A3 Novocastra 1:80 Microwave Breast cancer Nuclear
CDK4 C-22 Santa Cruz Biotechnology 1:300 Microwave Colon cancer Nuclear
P53 DO7 DAKO 1:50, 2 h Microwave Breast cancer Nuclear
P21waf SX118, DAKO 1:50, 2 h Microwave Epidermis Nuclear
Mdm-2 Monoclonal IF2 Oncogene 1:20, 2 h Microwave sarcoma Nuclear
P27 SX53G8, DAKO 1:80, 1 h None Breast cancer Nuclear
P16 6H12 Novocastra Lab 1:40 Microwave Epidermis Nuclear
Rb Rb1(recognizes phosphorylated & non-
phosphorylated protein) DAKO
1:80 Microwave Retinoblastoma Nuclear
Ki-67 MIB 1, Dako 1:50 Microwave Breast cancer NuclearBMC Clinical Pathology 2007, 7:4 http://www.biomedcentral.com/1472-6890/7/4
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Determination of p53 gene status
Exons 5–9 of the p53 gene were amplified separately using
p53  Gene Analysis Kit (Visible Genetics Inc., Toronto,
Canada) in all studied cases. Briefly, 3 ul of genomic DNA
were added to a 25-µl PCR mixture according to manufac-
turer's instructions and then cycled through 35 cycles con-
sisting of 94°C for 30 s, 60°C for 30 s, and 72°C for 60 s
in a thermo-cycler (Perkin Elmer, Norwalk, CT, USA).
PCR products were then visualized by electrophoresis in
an ethidium bromide-stained 1% agarose gel. Single
strand conformation polymorphism (SSCP) was per-
formed as previously described [14]. All PCR samples
with aberrant conformers on SSCP were sequenced using
nested CY5/CY5.5-labeled primers provided in the p53
Gene Analysis Kit (Visible Genetics Inc., Toronto, Can-
ada) according to supplier's instructions and analyzed
using the MicroGene Blaster Automated DNA electro-
phoresis unit (Visible Genetics Inc., Toronto, Canada)
Determination of cyclin D1, cyclin E and CDK4 gene status
was performed using the differential PCR assay (DPA) as
previously described with GAPDH as an internal control
[15].
Detection of DNA methylation in CpG islands of the Rb
gene was done using a methylation specific PCR.
Homozygous deletion (HZD) was assessed using a semi-
quantitative differential PCR as described by Nakamura et
al. [16].
Determination of p16 gene mutation
The presence of p16 gene mutations was assessed using
the SSCP/sequencing according to Tripathi et al. [17].
mdm-2 gene amplification was assessed using the primer
sequence and PCR conditions of Oda et al [18] with phe-
nyl alanine hydroxylase (PAH) as an internal control. The
level of mdm-2  gene amplification was determined by
comparing the intensities of the mdm-2  and PAH-PCR
products for each of the samples with SA-1 cells as a posi-
tive control (seven folds). Samples showing more than 2
fold amplification were considered positive.
Statistical methods
Statistical analysis was performed using the Stat View 4.5
software package (Abacus Concepts, Berkeley, CA). The
Mann-Whitney non parametric test was used to compare
the PIs of pairs of subjects and the Kruskal-Wallis test was
used for categorical data. Correlation between the indexes
was determined by a simple linear regression test. Kaplan-
Meier method and the log-rank tests were used for the sur-
vival analysis. Univariate and multivariate Cox propor-
tional hazards modeling were performed with overall
survival (OS) as the end point. The median time of fol-
low-up was 11.6 months for all patients and 33.5 months
for survivors. Values of p < 0.05 were considered to be sta-
tistically significant.
Results
Ki-67 expression
The positivity index for Ki-67 was significantly increased
with progression from NCT (< 0.1) to ISCC (40.5 ± 11) (p
= 0.003). Ki-67  expression in CINI was significantly
higher than in NCT (p = 0.01) (Figure 2d & Table 3).
Expression of cyclins and CDK
Cyclin D1 overexpression was detected in CINIII and ISCC
cases only. All samples positive for cyclin D1 expression
were scored (++) except for 6 cases of ISCC that scored
(+++). The PI was significantly higher in ISCC than in
CINIII (p = 0.001). Cyclin E expression was significantly
increased from CINI (16.7%; 18 ± 1.1) to ISCC (88.4% PI
= 97 ± 13.8), (p = 0.001). Similarly, CDK4 expression was
significantly increased from CINI to ISCC (p = 0.001) (Fig-
ure 1f, 1g & Table 3).
Table 3: The level of protein expression of different studied markers in normal, dysplastic and neoplastic cervical epithelium detected 
by immunohistochemistry
Marker NCT (20) CINI (n = 18) CINII (n = 11) CINIII (n = 38) ISCC (n = 43)
Pos. Cases PI* Pos. cases PI Pos. cases PI Pos. cases PI Pos. cases PI
Ki-67 5 (25%) < 0.1 6.5 ± 0.5 10 ± 0.45 21.6 ± 9 40.5 ± 11
Cyclin D1 0(0%) 0(0%) 0 (0%) 5(13.1%) 24.7 ± 3.6 18(41.9%) 63.2 ± 10.8
Cyclin E 0(0%) 3(16.7%) 18 ± 1.1 4(36.4%) 30 ± 4.4 21(55.3%) 60 ± 10.2 38(88.4%) 97 ± 13.8
CDK4 0(0%) 2(11.1%) 5 ± 0.5 4(36.4%) 12 ± 1.7 17(44.7%) 35 ± 4.6 40(93%) 92 ± 14.7
p53 0(0%) 0(0%) 0(0%) 7(18.4%) 44 ± 5.6 19(44.2%) 76 ± 9.1
p21waf1 3(15%) 2.8 ± 0.2 1(5.5%) 7 ± 0.5 1(9.1%) 9.2 16(42.1%) 58 ± 7.1 29(67.4%) 89 ± 10.6
mdm-2 0(0%) 0(0%) 0(0%) 9(23.7%) 66 ± 8.2 22(51.2%) 89 ± 10
p27KIP1 20(100%) 90 ± 8.6 18(100%) 77 ± 10.5 7(63.6%) 60 ± 11.7 10(26.3%) 20 ± 5.5 6(13.9%) 9 ± 1.1
p16INK4A 0(0%) 0(0%) 4(36.4%) 24 ± 4.7 24(63.1%) 70 ± 12.6 40(93%) 98 ± 12.0
Rb† 0 74 ± 11.6 0 68 ± 11.1 6(54.5%) 54 ± 8.6 21(55.2%) 25 ± 1.6 29 (67.4%) 7 ± 1.0
PI = Positivity index
†: Altered expressionBMC Clinical Pathology 2007, 7:4 http://www.biomedcentral.com/1472-6890/7/4
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On the other hand, cyclin D1 gene amplification was
detected in 20 (46.5%) ISCC and 7 (18.4%) CINIII cases
(The concordance between both techniques was 90 %).
Cyclin E gene amplification was detected in 2 cases
(11.1%) of CINI, 5 (45.5%) CINII, 21 (55.3%) CINIII and
38 (88.4%) ISCC (The concordance between both tech-
niques was 97%). CDK4 gene amplification was detected
in 2 cases of CINI, 4 cases of CINII, 15 cases of CINIII and
39 cases of ISCC (The concordance between both tech-
niques was 96%) (Figures 3, 4, 5).
Expression of CDKIs
Nuclear immunoreactivity for p21waf  was sporadically
detected in NCT, CINI and CINII. However, diffuse stain-
ing for p21waf was detected in CINIII and ISCC. There was
a significant difference in the PI of p21waf between CINII
and CINIII as well as between CINIII and ISCC (p = 0.01)
(Figure 2c & Table 3).
p27Kip1 expression was significantly decreased with disease
progression (p = 0.003). The protein was found in all NCT
and CINI, in 63.6% of CINII, 26.3% of CINIII and in
13.9%of ISCC (Figure 1a–c & Table 3).
p16INK4A  overexpression was detected in 4 CINII, 24
CINIII and 40 ISCC. The PI was significantly higher in
ISCC than in CINIII (p = 0.01) (Figure 1d, 1e & table 3).
Although abnormal conformers were detected in 3 ISCC
cases by SSCP, no mutations were found in any of them
by sequencing.
p53 gene status
p53  overexpression was detected in 18.4% CINIII and
44.2% ISCC cases only (Table 3). All positive CIN cases
were scored (++) except for a single case that was scored
(+) whereas 11 ISCC cases were scored (+++), 5 were (++)
and 3 were (+). There was a significant difference in the PI
between CINIII and ISCC (p = 0.01) (Figure 2a).
p53 gene mutations were detected in 5 (11.6%) cases of
ISCC only, 3 of them showed protein overexpression.
Four cases showed mutations in exon 7 (one had muta-
tion in codon 240 [AGT → ATT, S → I] and 3 in codon 249
[AGG → AGT, A → S]) and the remaining case showed
An ethidium bromide-stained 2% agarose gel for cyclinE gene  amplification, lane 1: MW, lanes 2–4: normal cervical tissue  samples, lanes 5–9: CIN cases, lanes 10–14: cases of invasive  squamous cell carcinoma Figure 5
An ethidium bromide-stained 2% agarose gel for cyclinE gene 
amplification, lane 1: MW, lanes 2–4: normal cervical tissue 
samples, lanes 5–9: CIN cases, lanes 10–14: cases of invasive 
squamous cell carcinoma. Lanes 10, 13, 14 show cyclinE gene 
amplification.
An ethidium bromide-stained 2% agarose gel for CDK4 gene  amplification, lane 1: molecular weight marker (MW), lanes  2–7: cases of invasive squamous cell carcinoma, lanes 8–12:  CIN cases, lanes 13–14: normal cervical tissue samples, lane  15: a negative control Figure 3
An ethidium bromide-stained 2% agarose gel for CDK4 gene 
amplification, lane 1: molecular weight marker (MW), lanes 
2–7: cases of invasive squamous cell carcinoma, lanes 8–12: 
CIN cases, lanes 13–14: normal cervical tissue samples, lane 
15: a negative control. Lanes 2, 3, 8 show CDK4 gene amplifi-
cation.
Cases of invasive squamous cell carcinoma showing a) strong  nuclear immunostaining for p53, b) diffuse nuclear staining  for mdm2, c) positive nuclear immunostaining for p21WAF and,  d) positive immunostaining for ki-67 Figure 2
Cases of invasive squamous cell carcinoma showing a) strong 
nuclear immunostaining for p53, b) diffuse nuclear staining 
for mdm2, c) positive nuclear immunostaining for p21WAF and, 
d) positive immunostaining for ki-67.
An ethidium bromide-stained 2% agarose gel for cyclinD1  gene amplification, lane 1: MW, lanes 2–8: cases of invasive  squamous cell carcinoma, lanes 9–14: CIN cases, lanes 15– 16: normal cervical tissue samples Figure 4
An ethidium bromide-stained 2% agarose gel for cyclinD1 
gene amplification, lane 1: MW, lanes 2–8: cases of invasive 
squamous cell carcinoma, lanes 9–14: CIN cases, lanes 15–
16: normal cervical tissue samples. Lanes 2,4,6,8,10,12,14 
show cyclinD1 gene amplification.BMC Clinical Pathology 2007, 7:4 http://www.biomedcentral.com/1472-6890/7/4
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double mutations in exons 5 (codon 132, 1 bp deletion)
and exon 8 (codon 290 [CGC → AGC, S → A]) (Figure 7).
None of the normal cervical tissue samples or cases of
CINI-III showed p53 gene mutations.
mdm-2 gene status
mdm-2 overexpression was detected in CINIII and ISCC
cases only. All CINIII cases were scored (++) whereas in
ISCC, 17 cases were scored (+++) and 5 were (++). There
was a significant difference in the PI between CINIII and
ISCC (p = 0.01) (Figure 2b & Table 3). mdm-2 gene ampli-
fication was reported in 9 CINIII cases and in 20 ISCC
cases. The concordance between both techniques was
95.1%.
Rb gene status
Normal expression of the Rb protein was reported in all
NCT and CINI, whereas altered expression was detected in
6 (54.5%) CINII cases, 21 (55.2%) CINIII and 29 (67.4%)
ISCC. There was a significant difference in the PI between
NCT and CINII (P = 0.031), CINII and CINIII (p = 0.021)
and between CINIII and ISCC (p = 0.021) (Figure 1h, 1i &
Table 3). HZD of the Rb gene was found in 20 (46.5%)
ISCC cases whereas PM was detected in 15 (39.5%) CINIII
and in 26 (60.5%) ISCC (Figure 6). 
Clinical correlations
There was a significant correlation between altered expres-
sion of Rb and p16INK4A (p < 0.001), p53 and mdm2 over-
expression (p = 0.003), cyclin D1 and CDK4 (p = 0.001) as
well as between increased cyclin E and reduced p27Kip1
expression in all studied groups (p = 0.011).
In the group of ISCC, there was significant relationship
between  p53,mdm2  and tumor size (p  = 0.003), and
between type (p = 0.01), as well as between p53 overex-
pression and lymphovascular invasion, and FIGO stage (p
= 0.003). Similarly, there was a significant association
between reduced p27Kip1, tumor size, tumor type (p  =
0.047), positive lymph node, stromal invasion (p  =
0.001&p = 0.024) and FIGO stage (p = 0.002); between
p21waf overexpression and tumor size (p = 0.001) and vag-
inal involvement (p = 0.042). Increased cyclin D1 was sig-
nificantly associated with tumor size (p  = 0.003) and
FIGO stage (p = 0.008) whereas, increased cyclin E expres-
sion was significantly associated with tumor size (p  =
0.001). A high Ki-67 index was significantly associated
with tumor size, lymph node involvement and FIGO stage
(Table 1).
For overall survival on univariate analysis, tumor size (p =
0.033), tumor differentiation (p = 0.047), lymph node
status (p = 0.021), FIGO stage (p = 0.011), a high Ki-67 (p
= 0.034), cyclinD1 overexpression (p = 0.011), p53 overex-
pression (p = 0.04) and reduced p27 (p = 0.023) were sig-
nificant (Table 4). However, multivariate analysis
revealed that FIGO stage (RR 4.211, 95% confidence
interval [CI] 3.281- 158.21, p = 0.003), Ki-67 (RR 1.527,
95% confidence interval [CI] 1.025- 20.7, p = 0.046) and
cyclin D1 overexpression (RR 1.296, 95% confidence
interval [CI] 3.029- 127.67, p = 0.008), p53 overexpres-
sion (RR 0.296, 95% confidence interval [CI] 3.460-
120.944, p = 0.001) and p27KIP1 loss (RR 3.650, 95% con-
fidence interval [CI] 1.307- 17.67, p = 0.014), were signif-
icant (Table 5)
Discussion
The present study is the first to investigate the role of a
large panel of cell cycle regulatory genes in Egyptian
patients with cervical carcinoma both at the gene and pro-
tein levels. The studied population was homogeneous
since all patients with CIN and ISCC were positive for
HPV16 and/or 18. Tissue samples representing the differ-
ent stages of transformation of normal cervical epithelium
into ISCC have been analyzed for the possible role of the
studied markers in etiopathogenesis of cervical carcinoma
and their prognostic value.
A case of ISCC showing mutation in exon 7 of the p53 gene  codon 247 by single stranded conformation polymorphism  and sequence analysis Figure 7
A case of ISCC showing mutation in exon 7 of the p53 gene 
codon 247 by single stranded conformation polymorphism 
and sequence analysis.
An ethidium bromide-stained 4% agarose gel for Rb gene  methylation lane 1: methylated control, lane 18: unmethylted  control, lanes 8–12: cases of invasive squamous cell carci- noma, lanes 12–17: CIN cases Figure 6
An ethidium bromide-stained 4% agarose gel for Rb gene 
methylation lane 1: methylated control, lane 18: unmethylted 
control, lanes 8–12: cases of invasive squamous cell carci-
noma, lanes 12–17: CIN cases.BMC Clinical Pathology 2007, 7:4 http://www.biomedcentral.com/1472-6890/7/4
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It has been shown that the E6 and E7 proteins of HR-HPV
types disrupt cell cycle checkpoints, particularly affecting
CDKI linked to the G1- and G2-checkpoints with conse-
quent accumulation of genetic aberrations [19]. To our
knowledge, the role of cyclins, CDKs and CDKI in ISCC
and its precursor lesions is not well defined yet. Moreover
no single study has investigated the contribution of these
proteins together and in association with other cell cycle
related genes such as p53, Rb and mdm-2. In the present
study aberrant expression of CDKs and their inhibitors
were detected at several points during the transformation
of HPV-infected cervical epithelium.
Cyclin D1 amplification and protein overexpression were
found in 46.5% and 41.9% of our ISCC cases as well as
in18.4% and 13.15% of CINIII cases only. Our results are
in agreement with Nicholas et al. [19] and Cheung et al.
[15]. In contrast, Bae et al. [20] reported reduced cyclin D1
mRNA and protein expression in cases of CIN and ISCC
compared to NCT. It is difficult to explain the controversy
between our results and those of Bae et al. [20]. However,
their study is one of the very few studies showing reduced
cyclin D1 in cervical carcinoma. Moreover, they reported
increased cyclin D1 expression with increasing severity of
the lesion from high grade squamous intraepithelial neo-
plasia (HSIL) to ISCC which makes a higher expression in
normal epithelium compared to the neoplastic one
unlikely.
Our study shows a stepwise increase in the expression
level of CDK4 from normal to tumor tissues indicating an
important role for CDK4 at an early stage of transforma-
tion of HPV- infected cervical epithelium. Our results con-
firm the few available reports in this context [15,8].
Although it is well known that cyclinD1 is necessary for the
activation of CDK, the concordance reported in the
present study between CDK4 and cyclin D1 expression was
49% only. We also detected increased CDK4 expression in
cases of CINI and CINII although these cases did not show
simultaneous increase in cyclin D1. This could be
explained by the involvement of other D-type cyclins such
as cyclin D2 and 3 in the activation of CDK4 [21]. Alterna-
tively, the D type cyclins may not be required at all for G1
progression in HPV-transformed cervical epithelium since
binding of HPV E7 protein to Rb leads to release of E2F
transcription factor omitting the role of cyclin D1 in cell
cycle progression [19].
Our results denote an important role for cyclin E in the
early stages of HPV-associated cervical carcinogenesis
since protein overexpression and gene amplification were
detected during progression from NCT into ISCC. We also
noticed a significant association between increased cyclin
E expression and reduced p27kip1. Our data confirm the
results of Dellas et al [21] who demonstrated a feed back
inhibitory loop between cyclin E and p27kip1. This suggests
the presence of a synergistic effect between both genes
which will eventually lead to enhanced progression
through the cell cycle as a consequence of the proliferative
effect induced by increased cyclin E expression and the loss
of the inhibitory function of p27kip1.
Inactivation of CDKIs  (p27kip1,  p21waf, p16INK4A) via
reduced expression was reported in various human
tumors [22]. In HPV-associated cervical carcinoma, the
situation is less clear since some studies showed that the
tumor suppressor activity of these proteins is overcome
through the action of the viral oncogenes E6/E7 without
any change in their expression level [22], others showed
that this applies to p21waf  and  p27kip1  only whereas
p16INK4A is usually down regulated [22-24]. Moreover, the
HR-HPV types were shown to impair the function but not
Table 5: Multivariate analysis of the clinicopathological factors 
and tested markers for overall survival
Predictive variables RR 95% CI P value
Tumor size 3.446 1.107–8.155 0.082
Tumor differentiation 4.073 0.792–20.957 0.093
Lymph nodes 3.921 5.283 – 12.711 0.075
FIGO Stage 4.211 3.281 – 158.21 0.003
Cyclin D1 1.296 3.029 – 127.67 0.008
p53 0.296 3.460–120.944 0.001
p21waf1 2.56 1.531–6.015 0.172
p27KIP1 3.650 1.307–17.67 0.014
Ki-67 1.527 1.025 – 20.7 0.046
Table 4: Univariate analysis of the clinicopathological factors and 
tested markers for overall survival
Predictive variables P value
Age (< 50; ≥ 50) 0.919
Tumor type 0.631
Tumor size (< 4 cm, ≥ 4 cm) 0.033
Tumor differentiation (well differentiated, poorly 
differentiated)
0.047
Lymph node status (positive, negative) 0.021
Stromal invasion (positive, negative) 0.664
Lymphovascular invasion (positive, negative) 0.831
Vaginal involvement (positive, negative) 0.532
FIGO stage (early, late) 0.011
Cyclin D1 0.011
Cyclin E 0.817
CDK4 0.532
p53 0.040
mdm-2 0.751
p21WAF 0.056
p16INK4A 0.855
p27KIP1 0.023
Rb 0.651
Ki-67 0.034BMC Clinical Pathology 2007, 7:4 http://www.biomedcentral.com/1472-6890/7/4
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the expression of the p21waf and  p16INK4A by rendering
them insensitive to cyclin-CDK  complex formation
whereas p27KIP1 is usually down-regulated [24].
In the present work, a stepwise decrease in p27kip1 expres-
sion and a stepwise increase in p16INK4A were found in cer-
vical epithelium as it progressed from normal to a
neoplastic one. Our results regarding p27kip1 expression
are in agreement with previously published data [8,24-
26]. In contrast, Shiozawa et al., [27] reported in their
study a strong p27kip1 expression in normal cervical epithe-
lia which was markedly reduced to a negligible level in
CIN samples. However, in ISCC cases they reported an
increased expression of p27kip1 and demonstrated that the
p27  protein was bound to cdk2 and cyclin E. Conse-
quently, the authors concluded that, p27kip1 expression
may be involved in the growth regulation of NCT however
aberrant function of the p27kip1 may occur in ISCC of the
cervix. Although we can not find a proper explanation for
this discrepancy in the results, we assume that the mecha-
nism proposed by Shiozawa et al. [27] might represent an
alternative pathway for p27kip1 inactivation in ISCC of the
uterine cervix through binding and sequestration by cdk2
and cyclin E which render it inactive just as the case with
p53 and mdm2.
In our study, p16INK4A overexpression was detected during
the early stages of cervical carcinogenesis although no
mutation was reported in any of the studied cases. We
therefore assume that inactivation of p16INK4A gene in
HPV-associated ISCC is possibly achieved via mecha-
nism(s) other than gene mutations. Among which is the
binding to- and sequestration by other cellular and/or
viral proteins. Our results are consistent with Volgareva et
al. [22] and Tringler et al. [28] who reported p16INK4A over-
expression in a high percentage of dysplastic and neoplas-
tic lesions of the cervix uteri. They also mentioned that
p16INK4A could be used as a surrogate marker for early
diagnosis of cervical carcinoma. However, our results
regarding p16INK4A gene mutations in ISCC contrast with
Tripathi et al. [17] who reported p16INK4A gene mutation
in 15% of their ISCC cases. A difference in sampling meth-
ods, clinical and virological features of studied cases or a
racial difference could be mentioned as possible explana-
tions for the controversial results between the two studies.
An interesting finding in this study is the significant
increase of p21waf which was recognized at CINIII and
ISCC cases only. Although it is expected that increased
expression of p21waf should suppress the progression of
cells in the cell cycle and consequently suppress cell
growth, all the cases that revealed p21waf overexpression
had a high Ki-67  positivity index. Several explanations
could be mentioned in this regard including: 1) the inter-
action between HPV E7 oncoprotein and p21waf which
abrogates its inhibitory effect on cyclin/CDK4 activities, 2)
the occurrence of checkpoint adaptation after constant
stimulation, 3) altered or inhibited binding to the CDK4/
cyclin D1 complex, or 4) mutations in downstream targets
of p21waf [3,8,10,28].
Our study is the first to assess RB gene HZD and PM in
addition to altered protein expression in cervical carci-
noma and its premalignant lesions. We detected altered
Rb expression in the early stages of cervical carcinogenesis
whereas PM and HZD were reported in CINIII and ISCC
only. Therefore, we assume that altered protein expression
in the early stages of neoplastic transformation could be
attributed to mechanism(s) other than gene deletion or
silencing by PM. Degradation by HPV-E7, sequestration
by other cellular proteins or inactivation by yet unidenti-
fied mechanism(s) could be mentioned in this context.
Our results regarding altered Rb expression are consistent
with the few available reports in this context [3,8,28].
Since all ISCC cases are HPV-16 or 18 positive, it is not
expected to find accumulation of the p53 nor the p53-
induced proteins in these cases. However, elevated levels
of p53 and p21waf proteins were seen in a relatively high
fraction of cervical cancer together with mdm-2 in CINIII
and ISCC cases. Our data are comparable to Tsuda et al.
[29] and Huang et al. [30] who found p53 overexpression
in 11.4% and 40.5% of HSIL compared to 56.6% and
30.7% of ISCC cases; respectively. Previous studies on
ISCC showed that p53 overexpression is not usually asso-
ciated with gene mutation but with sequestration by cel-
lular or viral proteins of which mdm-2 is a highly possible
candidate. This is in agreement with our results where p53
mutations were detected in 4 cases only whereas mdm-2
over-expression was present in 51.2% of ISCC, 13.7%
CIN.
In gynecologic oncology, valid prognostic factors are nec-
essary to define biologically similar subgroups for analysis
of therapeutic efficiency. In the present study cyclin D1,
p27, p53 and a high Ki-67 showed a prognostic relevance
as increased expression of cyclin D1, p53 and Ki-67 as well
as loss of p27 were highly correlated with the standard
clinicopathologic prognostic factors for ISCC and they
were significantly associated with reduced OS. Our data
regarding the prognostic value of cyclin D1 and p53 are in
agreement with Bae et al. [20] and Huang et al. [30],
respectively who demonstrated that cyclin D1 and  p53
overexpression are associated with decreased disease free
survival (DFS) and OS rates. Similarly, our data regarding
p27 are consistent with previous reports [16,22] which
considered p27KIP1 an independent prognostic factor that
significantly correlates with poor survival in ISCC.BMC Clinical Pathology 2007, 7:4 http://www.biomedcentral.com/1472-6890/7/4
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We conclude that, infection of cervical mucosa by HPV16
and 18 leads to deregulation of the cell cycle via altering
the expression level of certain genes. Whereas p27KIP1, cyc-
lin E, CDK4, p16INK4A and Rb aberrations are early events;
cyclin D1, mdm-2, p53 and p21waf aberrations occur late in
cervical carcinogenesis (Figure 8). Together, these altera-
tions lead to acceleration of the cell cycle with increased
proliferation rate, as indicated by a high Ki-67 PI, and
acquisition of more genetic damage. Our results also pro-
vide evidence that the application of immunohistochem-
ical tests for p16INK4A, cyclin E, p27KIP1 could help in early
diagnosis of cervical carcinoma since alterations affecting
the expression level of these proteins occur at an early
stage of cervical carcinogenesis. Therefore they could be
used as surrogate markers for early detection of ISCC and
for monitoring patients with cervical dysplasia. On the
other hand, p53, cyclin D1, p27KIP1 and Ki-67 are inde-
pendent prognostic factors in cervical cancer that could be
used for predicting the clinical outcome of those patients.
Conclusion
It seems that aberrations involving p27KIP1, cyclin E, CDK4,
p16INK4A are early events in HPV 16- and 18-associated cer-
vical carcinoma, whereas cyclin D1 and p53 pathway
abnormalities are late events. The use of immunohisto-
chemical tests for p16INK4Aand cyclin E, may be of help in
early diagnosis of cervical carcinoma. To predict the dis-
ease outcome of cervical cancer patients, only FIGO stage
p53, cyclin D1, p27KIP1 and Ki-67 are independent prog-
nostic factors.
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